Home
Live Updates
Retrospective Study Suggests Large Proportion of EU-Approved Oncology Drugs Offer Minimal or No Added Benefit : comparemela.com
Retrospective Study Suggests Large Proportion of EU-Approved Oncology Drugs Offer Minimal or No Added Benefit
Most oncology drugs approved by the EMA recover research and development costs within a few years, even if the drug is providing little added benefit.
Related Keywords
Utrecht ,
Netherlands ,
United States ,
Lourenst Bloem ,
Francine Brinkhuis ,
European Medicines Agency ,
Division Of Pharmacoepidemiology ,
Utrecht University ,
European Union ,
Clinical Pharmacology ,
Utrecht Institute ,
Pharmaceutical Sciences ,
Gastrointestinal Cancer ,
News ,
Global Oncology ,
Gi Cancer ,
comparemela.com © 2020. All Rights Reserved.